Lundbeck announced March 2018 acquisition of Swiss biotech Prexton Therapeutics for EUR 100M (~$123M) upfront plus up to EUR 805M (~$992M) in clinical, regulatory and commercial milestones (total up to ~$1.1B). Adds foliglurax, a Phase 2 mGluR4 positive allosteric modulator targeting OFF-time reduction and L-DOPA-induced dyskinesia in Parkinson's disease.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedMar 16, 2018
ClosedMay 08, 2018
Deal value$1.1B
Deal typeAcquisition/Merger
Therapeutic areaParkinson's disease (OFF-time and L-DOPA-induced dyskinesia)
IndicationsParkinson's disease (OFF-time and L-DOPA-induced dyskinesia)